MADISON, WI–(Marketwire – December 1, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that it is the exclusive sponsor of the American Cancer Society’s Fall 2010 Matching Grant Challenge, a national fundraising campaign that was launched in November.

As sponsor, TomoTherapy will contribute $1 for every $1 donated by the general public, up to $100,000, to support the American Cancer Society’s efforts to help people stay well and get well from cancer, find cures, and fight back against the disease. The Matching Grant Challenge ends on December 15, 2010.

“Every day, TomoTherapy’s innovative radiation therapy solution helps patients fight cancer. With our support of the American Cancer Society, we extend our impact beyond technology,” said Fred Robertson, M.D., TomoTherapy’s CEO. “In matching the generous contributions of individuals, TomoTherapy proudly strengthens the efforts of the American Cancer Society — from funding groundbreaking research to providing resources for patients, their families and caregivers at every step in the cancer experience.”

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

FREMONT, CA–(Marketwire – December 1, 2010) – GammaTech Computer Corp., a major international manufacturer and supplier of innovative notebook and tablet computers, brings its military-grade rugged design and versatile computing to the fast-paced healthcare environment with the MT10L clinical tablet PC. Featuring advanced Intel® Health Mobile Clinical Assistant Solutions reference architecture, a recognized leader in the industry, the MT10L is an ideal mobile solution for healthcare providers searching for an easier way to maintain accurate, timely and instantly accessible records.

“Our MT10L clinical tablet PC is both a simplification and an innovation when it comes to record-keeping for healthcare professionals,” stated Steven Gau, GammaTech president. “Its myriad features allow healthcare workers to make notes in patient-care records at the point of care and document patients’ conditions in real time, ensuring heightened accuracy in documentation. This leads to a reduction in medical errors, enhanced workflow, faster, safer patient care, better transcription efficiencies, better insurance practices and more accurate billing.”

At under three pounds, with a slim, clipboard-style design and molded ergonomic handle, the GammaTech MT10L clinical tablet PC is easy to carry and hold during those long shifts. The 10.4″ high-resolution (1024×768) XGA TFT LCD display features brightness adjustment, eliminating eyestrain, while the resistive touchscreen responds to both fingertips and the included stylus pen. Your shift will never be interrupted by the need to recharge, as hot-swappable twin battery packs provide up to eight hours of life. The fully sealed fan-less design offers ingress protection to guard internal components. In an environment where technology is susceptible to damage from slips and liquids, the MT10L is military-grade in its durability: the fully sealed design ruggedly protects internal components, making the tablet drop-proof, spill-proof, shock-proof, dust-proof, watertight and alcohol and disinfectant wipe resistant (to protect against cross contamination).

Recording patients’ progress as it happens is a snap — literally. The MT10L’s two-megapixel camera with auto-focus enables quicker, more detailed documentation of wounds, surgical sites, range of motion and other conditions, and photos can be saved directly to a patient’s electronic medical record. The MT10L is specifically designed to take advantage of all the features and innovations inherent in Electronic Medical Record advancements. Furthermore, the introduction of this line advances the fiscal incentive programs offered by the Federal government in order to promote electronic healthcare record adoption by clinicians and healthcare facilities. Other features include a docking station, AC power connector, built-in RFID reader and a barcode reader to help reduce prescription errors.

The GammaTech MT10L clinical tablet PC supports both Wi-Fi and Bluetooth technologies and runs on Windows 7 Professional, Vista Business and XP Tablet Edition operating systems.

Availability
The MT10L — along with the entire GammaTech product line — is available to healthcare professionals, hospitals, group purchasing organizations, government entities and universities through authorized GammaTech resellers nationwide. For more information, please visit www.gammatechusa.com.

About GammaTech Computer Corporation
For over two decades, GammaTech Computer Corporation is a leader in the design, manufacturing and sales of rugged and hardened notebook and tablet computers throughout North America. GammaTech promotes its award winning, built-to-order durable mobile computers to businesses, government, healthcare, fire, law enforcement and public safety entities. GammaTech is headquartered in Fremont, California, which provides the final assembly, inventory, service and technical support.

For more information, please visit GammaTech at www.GammaTechUSA.com.

All products/services and trademarks mentioned in this release are the properties of their respective companies.
© 2010 GammaTech Computer Corporation. All rights reserved.

Click here to see all recent news from this company

HUDSON, NY–(Marketwire – December 1, 2010) – Taconic, a leading provider of in vivo solutions to life science researchers worldwide, announced that its Cologne, Germany production program has earned accreditation from AAALAC International (the Association for Assessment and Accreditation of Laboratory Animal Care International). With this accreditation, all Taconic programs worldwide are now AAALAC accredited thereby assuring customers that Taconic meets the highest industry standard of quality, health, genetic integrity and care for its animal models.

AAALAC International promotes the humane treatment of animals in science through voluntary accreditation and evaluation programs. Taconic was one of the first suppliers to be accredited by AAALAC International in 1969.

“For more than four decades, through our voluntary participation in the AAALAC accreditation process, Taconic has demonstrated its commitment to the safe, humane treatment of the research animals that are vital to our clients’ biomedical research,” said Jeffrey J. Lohmiller, DVM, MS, ACLAM, Global Senior Director, Veterinary Sciences, Taconic. “Attaining AAALAC accreditation across all of our programs worldwide is an achievement that reflects Taconic’s unwavering focus on quality and accountability.” 

The rigorous accreditation process required both a stringent internal review by Taconic and a comprehensive, on-site assessment by AAALAC evaluators, reviewing the Cologne site’s entire animal care and use program. To maintain their accredited status, all Taconic programs undergo re-evaluation every three years as per AAALAC requirements.

According to AAALAC International, more than 800 companies, universities, hospitals, government agencies and other research institutions have earned this prestigious accreditation.

About Taconic
Taconic is a leading provider of life sciences solutions to researchers worldwide, offering innovative lab animal models and scientific services that facilitate in vivo studies and advance drug discovery. Taconic’s wide range of advanced solutions include custom genetically modified rat and mouse model generation and production, contract breeding, off-the-shelf model repositories, compound profiling, contract research, imaging, genetic monitoring and health testing. Headquartered in New York’s Hudson River Valley, Taconic operates seven breeding facilities and three service laboratories in the U.S. and Europe and maintains a staff of over 1,000 scientific specialists committed to technological innovation. Additional information about Taconic is available at www.taconic.com.

SPARTA, NC–(Marketwire – December 1, 2010) – Amano Pioneer Eclipse^® (“APEC”), a worldwide manufacturer of professional floor care products, makes it easy to be green even when cleaning carpets. Their EnviroStar Green^® carpet care system is an effective and cost saving method to meet many of today’s green requirements. The system is comprised of four products — a dual purpose extractor & pre-spray cleaner, an extraction rinse, a soil release bonnet buff and an all purpose spotter. 

APEC chemists developed EnviroStar Green from specific raw ingredients that met specific green requirements. The benefits of using the EnviroStar Green system however, go well beyond meeting strict environmental standards. “Our green products are not only earth friendly, they also reduce certain ill effects produced by other conventional systems,” states Jacqueline Van Delft, VP of International Operations at Amano Pioneer Eclipse. “We use raw ingredients that are not classified as skin sensitizers to lower irritancy commonly found in traditional chemistry. This produces a more comfortable and healthier environment for everyone.”

Most traditional cleaning processes leave some residue on the carpet. Not only can this residue trigger allergic reactions in many people, it also affects future maintenance and replacement costs. Acting like glue, residue can quickly attract new dirt to a recently cleaned floor. Commonly known as resoiling, this dirt build-up leads to more frequent cleanings that shorten the life of the carpet.

To minimize residue, Amano Pioneer Eclipse formulated EnviroStar Green products with pH levels less than 10. Compared to some traditional carpet products with levels as high as 11 to 13, a more neutral pH allows more of the chemical to be extracted, is less damaging to carpet fibers and retains existing stain blocking treatments that extend the carpet’s life. 

The EnviroStar Green carpet care system does more than reduce the environmental impact of traditional cleaning. Competitively priced, these products lower downtime and maintenance costs, extend carpet life, reduce cleaning frequency and improve the health and safety of the surrounding environment. And, most of all, they produce results as good as or better than their more harmful counterparts. It’s no wonder that professionals around the world are turning to Amano Pioneer Eclipse for all their carpet care chemicals. For more information on EnviroStar Green Carpet Products and numerous other Amano Pioneer Eclipse floor care systems, please visit www.pioneer-eclipse.com. In the US call 1-800-367-3550. For international inquires call 1-336-372-8080.

About Amano Pioneer Eclipse – since 1978, Amano Pioneer Eclipse has provided building service contractors with mechanical and chemical solutions for cleaning and maintaining all types of flooring.

Click here to see all recent news from this company

TAMPA, FL–(Marketwire – December 1, 2010) – Sage Healthcare Division, a unit of Sage North America and a major provider of EHR and practice management software and solutions serving approximately 80,000 physicians in North America, today announced that Northwest Primary Care, a 25 physician, physician-owned practice in southeast Portland, has selected Sage to provide the IMPAX PACS (picture archiving and communication system). This new medical imaging system will augment the practice’s existing Sage Intergy practice management and EHR system. 

Sage Healthcare Division offers the IMPAX, a comprehensive PACS, through an arrangement with Agfa HealthCare. The IMPAX solution will allow Northwest Primary Care to more efficiently manage its growing medical imaging services and improve efficiency in reading and reporting on medical imaging studies.

Northwest Primary Care is moving away from film and chose the PACS through Sage to improve patient care and increase quality outcomes, said administrator Michael Whitbeck. “We sought a sophisticated PACS system that will allow our radiologists and physicians to look at the film right from the record, and to allow for more mobility of our radiologists who will be able to view film from anyone, on or off site,” Whitbeck said.

PACS also will reduce the need for redeveloping images related to over and under exposed film, a common problem with film images, said Whitbeck. “We’ll be able to alleviate those issues with PACS, and from that perspective, improve overall quality of care for patients,” he said. 

Northwest Primary Care has four locations throughout southeast Portland, Oregon, and hosts more than 81,000 patient visits per year. In addition to implementing the Agfa HealthCare PACS system through Sage, it has used Sage Intergy EHR for its practice management and electronic health records since 2006. Sage Intergy EHR is fully compatible with the Agfa HealthCare PACS solution, and allows for the viewing of patient images through the EHR. Sage Intergy EHR also can integrate its Radiology Information Systems (RIS) with the Agfa HealthCare solutions.

“Sage remains dedicated to its clients and committed to health centers such as Northwest Primary Care because of the trust they place in our products to improve health outcomes for patients,” said Betty Otter-Nickerson, president of Sage Healthcare Division. “Providing a multitude of solutions, such as an integrated PACS solution to go along with our EHR, shows our dedication to improving practice efficiency and remaining true to our mission of being physician focused and patient centric.”

Sage is a reseller of the Agfa HealthCare PACS and Computed Radiology (CR) solutions and offers installation of the PACS software, along with user support and training.

Sage has provided healthcare software solutions to streamline patient care for nearly 30 years, and is a leading supplier of business management software and services, serving more than 6.2 million small and midsized business customers worldwide.

View Sage Healthcare Division YouTube interviews.

View Sage Healthcare Division information.

About Sage Healthcare Division
Sage Healthcare Division provides integrated electronic health records, EDI applications and practice management systems to approximately 80,000 physicians and thousands of ambulatory care practices throughout North America. These systems enable physicians and practice managers to better manage their practices and improve profitability. Sage Healthcare Division is based in Tampa, Fla., and is a division of Sage North America. For more information, please visit www.sagehealth.com or call (877) 932-6301.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.2 million small and midsize business customers. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,400 people and supports 6.3 million customers worldwide. For more information, please visit the website at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, the Sage logos, and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

SCOTTSDALE, AZ–(Marketwire – December 1, 2010) – The holidays are the perfect time to show loved ones just how much you care. This year give your family and friends the miCARD Gift Card. The only holiday gift card that could save their life in a medical emergency.

At $14.95, the miCARD Gift Card (www.micard.com/migift) is the perfect stocking stuffer to help ensure the health and safety of those you care about most. miCARD’s wallet card gives first responders a readable summary of a loved one’s vital medical information 24/7, worldwide. In less than one minute, miCARD ensures that medical personnel have the essential information they need to make lifesaving decisions from any location. The miCARD Gift Card can be created securely online and is offered as either a printed gift certificate or it can be emailed for those hard-pressed to meet holiday postal deadlines.

“The holiday season reminds us of how much we care about family and friends. Most of us would do anything to ensure their health and safety,” said Dr. James Kelley, a practicing ER physician and co-founder of miCARD. “We wanted to create a holiday gift that offered real value and could actually save lives. Carrying medical information is a proactive step that could both improve your care and save your life.”

Are You Prepared for a Medical Emergency?
1 in 3 Americans will experience a medical emergency this year, yet most of us carry nothing that describes our unique medical background or identifies loved ones to contact in the event of a medical emergency. It’s critically important that individuals of all ages organize and manage their personal medical information in preparation of an unexpected medical event.

miCARD is the only medical information card and online Personal Health Record designed by an emergency physician. miCARD’s wallet card is designed to provide emergency personnel, in the field, a readable summary of a users vital medical information such as: medical conditions, critical medications, emergency contacts, allergies and more. The portable medical card is further supported by an online Personal Health Record containing additional medical information: advance directives, physician contacts, EKG, lab results, and current medications. All personal medical information is stored securely online and viewable at the miCARD website 24/7 by treating medical providers worldwide.

miCARD’s Holiday Gift Card is a low cost solution to the problem of emergency preparedness and care. To order your miCARD Gift Card visit www.micard.com/migift

About miCARD®
miCARD® is a physician-designed, medical information card and online Personal Health Record designed to optimize emergency medical care. miCARD’s proprietary solution improves the flow of critical care information and ensures medical personnel have immediate and secure access to a user’s vital medical information 24/7, worldwide. For more information about miCARD, please visit www.micard.com or contact us at (866) 596.2956.

Click here to see all recent news from this company

TOLEDO, OH–(Marketwire – December 1, 2010) – Cardiothoracic Surgeons for Northwest Ohio and The Toledo Hospital are now in the nation’s top 12% of hospitals for heart surgery. This is according to a three-star comprehensive rating system, developed by The Society of Thoracic Surgeons (STS), which compares the quality of heart surgery in hospitals across the country. A three-star rating is the highest designation that a hospital can attain for quality and clinical excellence. Cardiothoracic Surgeons for Northwest Ohio was compared to more than 1,000 surgical groups.

Hospitals are scored on performance in the following four categories — patient survival, absence of surgical complications, recommended medications, and optimal surgical technique. The ratings reflect results from isolated heart-bypass operations called coronary artery bypass grafting to newer versions, which include minimally invasive bypass and other complex cardiac procedures.

“I am grateful to my partners and colleagues at The Toledo Hospital who have worked diligently for years to reach this incredible milestone,” said Michael Moront, MD, senior partner, Cardiothoracic Surgeons for Northwest Ohio. “When patients enter our doors, they can feel confident that they will be receiving the very best care from one of the nation’s leading medical groups.”

Consumers can easily see how surgical groups compare with national benchmarks for survival, complications, and other measures by visiting www.consumerhealthreports.org.

About STS
The Society of Thoracic Surgeons is a not-for-profit organization representing more than 6,000 surgeons, researchers and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus as well as other surgical procedures within the chest. Founded in 1964, the mission of STS is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy. Its National Adult Cardiac Surgery Database includes more than 4 million surgical records and covers roughly 90% of the more than 1,000 surgical groups in the U.S. that perform cardiac surgery, making it the largest such registry in the world.

About Cardiothoracic Surgeons for Northwest Ohio
Cardiothoracic Surgeons for Northwest Ohio is a member of ProMedica Heart and Vascular Institutes, a collaboration of physicians, technology and specialty services. The group provides a comprehensive scope of leading edge patient care and state-of-the-art surgical procedures, including minimally invasive procedures, bloodless surgery, pediatric cardiac surgery, aortic valve repair and replacement and more. Its team of board-certified physicians, specialists and medical staff make up the largest cardiothoracic surgical program in northwest Ohio.

For more information about cardiac services at ProMedica Health System, visit www.promedica.org.

Cardiothoracic Surgeons for Northwest Ohio and The Toledo Hospital are members of ProMedica Health System. ProMedica, a mission-based organization, was formed in 1986 and is a Toledo, Ohio-based, not-for-profit healthcare organization with more than 14,000 employees; 3,000 physicians and more than 306 facilities in Ohio and Michigan. ProMedica serves more than 2.73 million patients annually and includes 11 hospitals; ProMedica Continuum Services with senior, hospice, rehabilitation, and integrative services; ProMedica Physician Group, a network of more than 315 primary care and specialty physicians; and Paramount Health Care, the largest HMO in northwest Ohio. For more information, please visit www.promedica.org.

TRAVERSE CITY, MI–(Marketwire – December 1, 2010) –  Just ten weeks after Versus Technology, Inc. (Versus) (PINKSHEETS: VSTI) was selected to support the Bethesda Hospitals’ Emergency Preparedness Partnership (BHEPP) Real-time Locating System (RTLS) initiative, the Versus Advantages^™ system was recently utilized during the organization’s disaster preparedness drill.

The October 14, 2010 drill was the sixth annual Collaborative Multi-Agency Exercise (CMAX-10) since the BHEPP was formed in 2004, and the first to utilize RTLS for continuity of patient information. Participating organizations included Suburban Hospital, Johns Hopkins Medicine, the National Naval Medical Center (both trauma centers), the U.S. NIH Clinical Center, and the National Library of Medicine. The drill was designed to test the medical readiness and response proficiency supposing a mass casualty in the National Capital Region. Surge capabilities and patient tracking were key components to be tested.

The BHEPP began exploring RTLS options after the inability to track patients during a mass casualty event had been documented as a gap in multiple real disasters. The U.S. Navy produced a video for CMAX-09, in which, Brian Grangnolati, President, Suburban Hospital states, “If you think about what the biggest problem is in any crisis, it’s communication and moving information” as he explains the need for RFID / RTLS. Versus’ RTLS was selected to enhance communication and keep information tied to patients, even as they are moved from facility to facility.

The BHEPP’s goal is to create a sustainable response model that can be replicated in other areas, especially densely populated areas at risk for national disasters or terrorist attacks. “Having real-time information related to the victim’s arrival and location was immensely helpful to the first-time Incident Commander in his decision making,” says Cindy Notobartolo, Division Director ED/Trauma, Safety & Security Services at Suburban Hospital. “Within our patient information system, the patient’s location was tied to triage and treatment data and made available in real-time to all emergency care personnel. The external evaluators were impressed that our tracking ability was 100% throughout the exercise.”

During the drill, as victims arrived at Suburban Hospital triage area, they were decontaminated, triaged and assigned Versus ID badges which were worn clipped to the victim’s clothing. A photo of the victim was also taken to support Lost Person identification and family reunification efforts. Emergency personnel then transported the patient to the appropriate treatment area.

The Versus ID badges, which emit digitized infrared (IR) and radio-frequency identification (RFID) signals, immediately communicated the patient’s location and triage level to care providers and Central Command via the BHEPP’s patient information system. When patients were reassessed, treated or moved to other areas, their locations were updated in real-time. Location of key personnel and equipment was also provided in real-time.

Versus prepared views and rules to support the key RTLS drill functionality as outlined below.

1. Real-time locating of all patients from decontamination and triage through discharge or hospital admission. 
2. Rules-based pediatric monitoring, with location-based alerts to help ensure children are secure and monitored at all times. The CMAX-10 drill did not take advantage of the dedicated pediatric area; however, the rules for monitoring and securing pediatric patients are in place and fully functional for future use. 
3. Real-time locating of critical equipment to decrease time to locate, improve utilization and support sharing across participating facilities. 
4. Web service integration with National Library of Medicine’s Patient Tracker for badge assignments, triage level and patient demographic information as it became available to the provider.
5. Real-time locating of key mass casualty incident personnel to improve communication and enhance decision-making capabilities of the Incident Commander. 
6. Tracking the evacuation of current hospital patients and their arrival at remote partner facilities for expanded surge capacity.

CMAX-10 was a valuable exercise for both the BHEPP and Versus; each organization identified areas for improvement related to expanded use, patient identification, training, information availability, advanced rules for patient transfer and make-ready operations. They look forward to building on this foundational experience to enhance communication and safety during future drills and in the event an actual response is required.

About BHEPP
This partnership is a first-of-its-kind collaboration that links military, federal, local and private mass disaster medical response efforts within the national capital area. Established in 2004, the partnership is now a model for other health care agencies throughout the country.

About Versus Technology, Inc.
Established in 1988, Versus Technology, Inc. specializes in real-time location systems (RTLS) for healthcare. Used for enterprise patient tracking, bed management, asset tracking, and nurse call automation, Versus Advantages™ improves patient flow and documentation of caregiver and patient interactions, while enhancing communication and efficiency. Exclusively endorsed by the American Hospital Association, the Versus Advantages infrared (IR) and Active RFID solution is responsible for clinical-grade location and automation at a number of hospitals, clinics and long-term care facilities worldwide. To learn more about Versus Technology, Inc. (PINKSHEETS: VSTI), our technology and client successes, visit www.versustech.com and take the Advantages Tour.

Safe Harbor Provision
This release may include forward-looking statements which “bespeak caution,” and which are subject to risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. The statements are made only as of the date of this release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances.

Click here to see all recent news from this company

ATLANTA, GA and BOSTON, MA–(Marketwire – December 1, 2010) – LumaMed LLC has entered into an initial agreement with Massachusetts General Hospital to commercialize an imaging system developed at the Wellman Center for Photomedicine that could revolutionize cancer surgery.

The technology is complementary to that previously licensed by LumaMed from Providence Hospital in Oregon for teledermatology imaging, and has the demonstrated ability to provide real-time surgical guidance, enabling a surgeon to “see” cancer margins.

LumaMed’s cancer imaging technology addresses an estimated $1 billion market opportunity for products that improve efficiency and efficacy in cancer removal procedures. Cancer margin delineation is critical in instances where tissue preservation is important, including skin, head and neck, breast, prostate and brain surgeries.

LumaMed is initially focusing on skin cancer, which is the most common of all cancers. Each year, over one million new cases of skin cancer are detected and many require painstaking and expensive Mohs surgery. Once cleared by the FDA, LumaMed plans to market the new devices to Mohs skin cancer surgeons as a visual aid to help eliminate the need for more than one surgical stage, thus improving patient care and creating a substantial economic benefit.

“In combination with a trained physician, we believe LumaMed’s technology could complement histopathological evaluation, help accurately define margins and reduce the occurrence of biopsies,” said Mark A. Samuels, chief executive officer of LumaMed. “The technology agreement with Massachusetts General Hospital will provide us with the additional tools necessary for development and commercialization of our image-guided surgical systems for the real-time evaluation of skin lesions and other cancers.”

LumaMed is combining two powerful approaches for rapid, easy and cost-effective onsite and remote evaluation of suspicious skin lesions using polarization-based spectroscopic imaging technology. Called “Polarization Subtraction Imaging,” PsiScan technology selectively samples the dermal/epidermal junction and papillary dermis, where cancer originates, and enhances image clarity by rejecting surface scatter and light from deeper layers. This results in images with significantly greater clarity and contrast for improved tumor identification and margin delineation. Clarity and contrast is required in skin cancer evaluation to recognize the disruption of the rich texture of the papillary dermis or to detect tumor silhouettes that identify basal cell carcinomas. Such disruption is difficult to discern with existing dermatoscopes or point-and-shoot digital cameras.

About LumaMed, LLC.
LumaMed is developing devices that provide rapid, easy and improved imaging of cancer based on patented “Polarization Subtraction Imaging” (PSI) technology. LumaMed’s revolutionary cancer visualization tools enable real-time imaging of cancer margins during surgery with an accuracy approaching that of conventional pathology. In addition to the initial focus on skin cancer, the approach can be used with other cancers such as prostate, breast, and head and neck cancers. LumaMed products have not been cleared by the FDA for sales in the U.S. and are not presently being offered for sale. For more information, visit www.lumamed.com.

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Dec. 1, 2010) – Premier Diagnostic Health Services Inc. (CNSX:PDH) (“PDH”) announces the offering of two non-brokered term sheets to raise a total of $350,000.

The two non-brokered term sheets: “Offering A” and “Offering B” are offered to accredited investors.

1. Offering A consists of 625,000 Units at $0.40 per Unit, each Unit consisting of one Share and one half Warrant, with a minimum subscription of 125,000 Units for $50,000, for a total Offering of $250,000. One Half Warrant is included with each Unit; a full Warrant entitles the holder to subscribe for a further Share of PDH for $0.60 per Share. Warrants will be non-transferable and will expire on June 30, 2011.

2. Offering B consists of 250,000 Shares of Premier Diagnostic Health Services Inc. (“PDH”) to raise a total of $100,000. The price per Share is $0.40.

Both “A” and “B” Offerings will expire at 5:00 p.m. on December 20, 2010.

The proceeds from the term sheets will be used to:

1. Identify a second hospital in the metropolitan area of Beijing, China (in addition to PDH’s already established Center), for the establishment and joint operation of a Center for Advanced Diagnostics using PET-CT scanning for the diagnosis of cancer, with the objective of entering into a definitive agreement within three months;
2. Identify between one and three hospitals in the Pearl River Delta region of Guangdong province, China, particularly in the metropolitan area of Guangzhou, for the establishment and joint operation of Centers for Advanced Diagnostics using PET-CT scanning for the diagnosis of cancer, with the objective of entering into definitive agreements within six months; and
3. General working capital purposes.

The non-brokered private placement offering announced November 3, 2010 was not proceeded with.

About Premier Diagnostics Health Services Inc. (CNSX:PDH)

As leaders in advanced health and education with the international medical community, PDH is rolling out its global strategy of establishing a network of Centres for Advanced Diagnostics in Canada and China. By utilizing MRI and PET-CT, the most advanced medical diagnostic imaging technology available and the production of FDG, the radiopharmaceutical tracer used in oncology PET procedures; PDH is uniquely positioned to deliver continued innovation, growth and profitability.

UTICA, NY–(Marketwire – November 30, 2010) – CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the Company has amended its existing senior credit facilities to provide for a five-year, $250 million senior secured revolving credit facility. The term loans currently outstanding will remain in place. A group of ten financial institutions have agreed to participate in the revolving credit facility, with JP Morgan Chase Bank, N.A. as Administrative Agent. The revolving credit facility was arranged by J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated (successor by merger to Banc of America Securities LLC) as joint lead arrangers and joint bookrunners.

The amendment increases the revolving line of credit to $250 million and extends its term to November 30, 2015. Interest on drawn amounts is based on a pricing grid determined by the Company’s senior secured debt leverage ratio. At the present leverage ratio, interest cost is equal to LIBOR plus 1.75% and the fee on undrawn commitments is equal to 25 basis points. The agreement also permits a $75 million expansion of the revolver with consent of lenders participating in the expansion.

“We are pleased that our bank lenders have provided this increased credit facility with terms we consider favorable to CONMED,” said Mr. Joseph J. Corasanti, President and Chief Executive Officer. “We do not anticipate that interest expense will be materially affected by the new revolver.”

The new facility will be used to refinance the existing $49 million outstanding on the previous revolving credit facility, eliminate the previous receivable financing facility and for general corporate purposes. It is also intended to provide liquidity should the Company be required to fund the $112 million face amount of 2.5% Senior Subordinated Notes which are puttable on November 15, 2011. 

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use the Company’s medical devices. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products worldwide from several manufacturing locations.

Forward Looking Information

Certain statements made herein constitute forward-looking statements. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. They are based upon management’s expectations and involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements therein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to: (i) the failure of any one or more of management’s assumptions to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and Quarterly Reports on Form 10-Q; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition (and its integration) or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation, or litigation; and/or (viii) the Company’s ability to devise and execute strategies to respond to market conditions.

AUSTIN, TX–(Marketwire – November 30, 2010) – ProAssurance Corporation (NYSE: PRA) today completed its previously announced acquisition of American Physicians Service Group, Inc. (“APS”) (NASDAQ: AMPH). As a result of the merger, APS is now a wholly-owned subsidiary of ProAssurance.

The Chairman and Chief Executive Officer of APS, Ken Shifrin, said, “We’ve found the ideal partner to carry on the physician-focused traditions of APS. We know that ProAssurance will continue to serve our 6,800 insureds with the individual attention that is a part of our mutual corporate cultures. The last decade has resulted in a spectacular 36% average annual increase in APS’ stock price, from $1.50 to $32.50, and I want to thank our shareholders for their trust and for the opportunity to lead the company during this exciting time. I also want to say what an honor it has been to work with the board of directors and employees of APS and to thank them for their loyalty and dedication.”

“We are excited about the opportunities this transaction creates for us,” said ProAssurance’s Chairman and Chief Executive Officer, W. Stancil Starnes. “Not only does it give us significant market presence as the second largest writer of medical professional liability (MPL) insurance in Texas, it also enhances our presence in Oklahoma and Arkansas. We expect to leverage the skill and dedication of APS’ employees to deliver an unmatched level of service and financial strength to policyholders in these three key states. Additionally, we believe our shareholders will see benefits as well, as we expect to grow profitably during a challenging time in our business.”

Under the terms of the merger, each share of APS stock was redeemed for $32.50 in cash. Shareholders whose stock is held by a broker or in direct registration will be paid automatically. Those APS shareholders with stock certificates will receive instructions by mail for surrendering their shares in order to receive payment. Shareholders with questions about the share conversion process may contact American Stock Transfer & Trust at (877) 248-6417.

As a result of this transaction, APS’ common stock will cease to trade on the Nasdaq Stock Market prior to the open of business on December 1, 2010, and will thereafter be delisted.

About APS

APS is an insurance holding company with subsidiaries that provide medical malpractice insurance for physicians and other healthcare providers. APS is headquartered in Austin, Texas. Further information about the company is available on the Internet at www.amph.com.

PRINCETON, NJ–(Marketwire – November 30, 2010) –  To assist companies in managing their healthcare insurance options and show third party administrators (TPA), insurers and physicians how to react appropriately, Health Options Worldwide (HOW), an online vacation surgery resource, is offering a free webinar. Titled “Health Care Trends and Employers: New Strategies for a Changing Marketplace,” the webinar takes place Thursday, December 2nd, at 10 am EST and 4 pm EST. HOW, an international and domestic medical travel and medical tourism agency, will cover the current state of the healthcare marketplace as well as value-based and competitively priced key service to businesses.

Participants can register for 10am EST: https://www3.gotomeeting.com/register/526273158

Participants can register for 4pm EST: https://www3.gotomeeting.com/register/505357078

If participants have any questions or problems registering for the webinar, please contact Chris Peterson at 1-877-234-1345 or via email at: [email protected]. For more information, visit the HOW website at: www.healthoptionsworldwide.com

“Due to rising healthcare costs, companies need new strategies to reduce healthcare spending, improve the quality of care, and educate employees to take a more active role in their healthcare. Employers are afraid of the high costs that come with a self-funded employer solution, but yet they still want to provide health insurance coverage for their employees,” said David Goldstein, president of HOW.

Words like high deductible health plan surgery and voluntary surgery networks will become very popular in the healthcare market. As employee benefits claims and costs continue to rise, employers, TPAs and doctors can benefit from this webinar, says Goldstein. Employers can learn new ways to control risk and encourage employees to become more proactive in managing their healthcare and healthcare spending.

Current healthcare reform stipulations have not reduced claims or costs. Inflation, increased use of services, aging population, changes in provider treatment patterns, medical technology and drug therapy improvements have also influenced the upward healthcare spending trend. “The cost of employer health plans will probably increase within the next six months,” said Goldstein, quoting a survey by Wells Fargo Insurance Services.

Value based healthcare plans and supplemental healthcare solutions are affordable coverage options for businesses that can benefit workers. An increasing number of employers are researching different types of health insurance plans for their employees, knowing they can help them in many different ways.

“HOW leverages the growing trend of consumer-driven health care by connecting patients with physicians that offer high quality, low cost healthcare in the United States as well as internationally,” said Goldstein. He continued by saying that medical tourism will definitely affect the next generation of PPO’s by giving employees more local and regional treatment options with substantial discounts and improved outcomes.

Click here to see all recent news from this company

ATLANTA,GA–(Marketwire – November 30, 2010) – Clinigence, LLC, a health information technology company focused on the development of clinical business intelligence tools for accountable care organizations (ACOs) and healthcare providers, today announced that Steven M. Ornstein, M.D. has joined the Clinigence Advisory Board overseeing the development of the Clinigence collaborative software-as-a-service (SaaS) platform, helping care providers deliver quality care cost-efficiently.

Dr. Ornstein is a professor at the Department of Family Medicine and Graduate Studies at the Medical University of South Carolina (MUSC) in Charleston. He is also the founder and director of the Practice Partner Research Network (PPRNet) — the nation’s oldest and one of the largest practice-based research networks, operating for over 15 years and covering over 140 practices, 740 care providers and 1.8 million patients in 38 states.

Dr. Ornstein received his BA degree from Dartmouth in 1978 and his MD degree from Duke in 1981. He completed his residency in family practice at MUSC in 1985. He is board certified in family practice and has practiced continuously at MUSC Medical Center since 1985. Dr. Ornstein is a member of the American Academy of Family Physicians. He has led and participated in dozens of research studies on improving the quality of care through prevention, patient engagement and adherence, evidence-based guidelines and the use of information technology. At PPRNet, Dr. Ornstein has pioneered and perfected the translation of research into clinical practice to achieve real, measurable improvements in patient care.

“We are extremely pleased to welcome Dr. Ornstein to our advisory board,” said Kobi Margolin, Clinigence’s CEO. “We believe that his depth of knowledge in the area of translating scientific evidence into real-life improvement in patient outcomes will help us achieve the full potential of our unique and timely clinical business intelligence platform.”

About Clinigence

Clinigence, LLC, in Atlanta, is a health information technology company. Conceived in 2009 and launched in 2010, Clinigence develops, publishes and delivers collaborative software-as-a-service (SaaS) to help healthcare providers derive business value from clinical data and quality patient care. The Clinigence solution is tailored to the emerging needs of healthcare providers due to the shift of the US healthcare system from volume- to value-based purchasing and the growing demand for quality patient care. More information can be found at http://www.clinigence.com or contact Kobi Margolin at [email protected] or +1-678-466-6650.

CINCINNATI, OH–(Marketwire – November 30, 2010) –  “Using Benchmarks: The Good, The Bad, and The Ugly,” a new guide from Compass Clinical Consulting authored by Shawna O’Neill, RN, MHA; Eric Dam, MHA and Compass Clinical President Cary Gutbezahl, MD, reveals the positives and negatives of hospital benchmarking.

THE BENCHMARKING PROBLEM — ONE-DIMENSIONAL MEASUREMENT

Measurement is the cornerstone of assessing the performance of a hospital department. But, the problem is that benchmarks are one-dimensional, while real work is not. Designing productivity processes using benchmarks can cause problems if not done correctly.

BUILDING A CULTURE OF PRODUCTIVITY

“Using Benchmarks: The Good, The Bad, and The Ugly” shows how hospital leaders and managers can employ benchmarks to build a culture of productivity and provides strategies to:

• Help struggling managers meet their productivity targets while gaining buy-in from staff members
• Optimize workforce productivity using realistic benchmarks as guidelines, not mandates
• Ensure that leaders, managers, and employees “speak the same language” by establishing common definitions of key terms
• Create appropriate staffing levels to meet department workloads

ADD VALUE AT EVERY STEP

In hospital productivity design, every step within every process change should add value to the patients and the financial stability of the hospital. Whether you choose to approach productivity department by department or house-wide, the strategies in “Using Benchmarks: The Good, The Bad, and The Ugly” will guide your productivity transformation process.

To learn more download “Using Benchmarks: The Good, The Bad, and The Ugly.”

RELATED LINKS:

• Hospital Productivity Without Fear 
• Hospital Decisions Today Will Shape Your Hospital’s Future Workforce

About Compass Clinical Consulting
Compass Clinical Consulting helps hospitals reduce the cost of providing safe, quality patient care. Founded in 1979 and based in Cincinnati, OH, Compass has helped hundreds of hospitals and health systems prepare for accreditation, optimize labor cost management, manage clinical resources, and improve patient throughput and physician relations.

Click here to see all recent news from this company

DEURLE, BELGIUM–(Marketwire – November 30, 2010) – Remedent, Inc. (OTCBB: REMI), an international company specializing in research, development and the manufacture of oral care and cosmetic dental products signed an agreement with Small Caps Finance SA to open at least two Glamsmile Studios in Brussels, Belgium and Milan, Italy with an option for Rome, Italy as well.

SCF will provide all the necessary financing to a joint venture between both entities, where Remedent/Glamsmile will be the majority owner and provide all the necessary product and support to open the Studios. Glamsmile will operate and manage the Studios under the same formula for success as it does in Europe and Asia. It is anticipated that both Studios will open prior to the conclusion of our year end, namely March 31, 2011.

“The direct retail model of opening Studios in both Asia and Europe has been the reason for our financial turnaround as opposed to our previous wholesale (B2B) model via a distributor. This has led to two consecutive profitable quarters since the beginning of our financial year, April 1, 2010. In addition to western Europe, we will continue with our Glamsmile Studio expansion in Asia as well where we anticipate opening our Shanghai superstore in early 2011. I am very excited about our new venture with SCF for western Europe which will give us further exposure into two new markets, namely Milan and Brussels. The locations for our two new Studios have already been determined and they will be based in the most affluent shopping areas of both major cities. I look forward to the opening of both these two new locations where we expect the financial success to continue as we have experienced with our other Studios located in both Europe and Asia,” said Guy DeVreesse, the CEO of Remedent.

SCF currently has investments in both the pharmaceutical and health care industries. “The Glamsmile concept is unique and we are very excited about introducing beautiful smiles into new markets,” said Mr. Bernardo Ruzziconi, SCF, Chief Executive Officer.

About Remedent.

Remedent, Inc. specializes in the research, development, manufacturing and marketing of oral care and domestic dentistry products. The company serves the professional dental industry with breakthrough technology for dental veneers. These products are supported by a line of professional veneer whitening and teeth sensitivity solutions. Headquartered in Belgium, Remedent distributes its products to more than 35 countries worldwide. For more information, go to www.remedent.com

Forward-Looking Statements

Statements in the press release that are “forward-looking statements” are based on the current expectations and assumptions that are subject to risks and uncertainties. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Remedent’s actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “believes,” “belief,” “expect”, “intends,” “anticipate,” “anticipates,” “plans,” “projects,” “project,” to be uncertain and forward looking. Actual results could differ materially because of facts such as Remedent’s ability to achieve the synergies and value creation contemplated by the proposed transaction. For further information regarding risks and uncertainties associated with Remedent’s business, please refer to the risks described in Remedent’s filings with the Securities and Exchange Commission, including but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. We undertake no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of the press release.

LOS ANGELES, CA–(Marketwire – November 30, 2010) – MMRGlobal, Inc. (OTCBB: MMRF) (MMR) today announced it has signed a settlement agreement with the Lymphoma Research Foundation (LRF), resolving its lawsuit with LRF and giving the Company exclusive control of certain data and tissue samples created during trials of Favrille, Inc.’s FavId™ vaccine. The assets had been the subject of an ownership dispute with LRF. The Company acquired the FavId intellectual property, along with other biotech assets, from its reverse merger with Favrille, Inc., a San Diego biotech company, in January 2009. More than $140 million was spent on the development of the vaccine and other biotech assets and related patents. 

According to Kathleen M. Smith, a principal at Translational Medicine Consulting and a biorepository expert who provided expert testimony in the MMR litigation with LRF, the tissue samples could have values substantially in excess of one million dollars per set. When combined with clinical data and associated intellectual property belonging to MMR, the values could be significantly greater. 

“We will continue to explore licensing opportunities for these biotech assets, patents and other intellectual property with pharmaceutical companies, universities and institutional investors to create future streams of revenue for our shareholders,” said Robert H. Lorsch, MMRGlobal CEO. “I look forward to these assets being put to use to help find additional treatments for Non-Hodgkin’s Lymphoma and other related diseases while generating licensing revenues to help finance the Company’s primary business, namely the development and distribution of its MyMedicalRecords Personal Health Record and MMRPro Electronic Health Record products and services.”

MMR contended that prior to the merger, portions of the Company’s intellectual property were transferred by previous employees and or consultants of Favrille to third parties, including Lymphoma Research Foundation, without the knowledge and consent of Favrille’s Board of Directors or Science Committee. After MMR learned of the transfer, the Company pursued LRF to regain control of the data and tissue samples on behalf of its shareholders.

As part of the settlement agreement, the Lymphoma Research Foundation also settled a complaint filed in Los Angeles Superior Court by The RHL Group, Inc., a creditor of MMRGlobal, against LRF and others involving the transfer of the data, tissue samples and other assets which previously were the property of Favrille. Although The RHL Group case against LRF is settled, the case against the other named defendants is still active.

Over the last two years, MMRGlobal has been working to maximize the value of its biotech assets by perfecting its worldwide patent portfolio, regaining control of its anti-CD20 antibodies and FavId intellectual property including tissue samples, and developing licensing opportunities for the data and materials for use in Non-Hodgkin’s Lymphoma, target validation and other therapeutic research. As part of the settlement agreement, MMRGlobal shall cause the assets or portions of them to be used in further medical research.

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMRGlobal, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements regarding MMRGlobal, Inc.’s assets including but not limited to its primary Health IT businesses, samples and data from vaccine and clinical trials, and anti-CD20 antibody assets. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related but not limited to changes in MMRGlobal, Inc.’s business prospects, its results of operations or financial condition, government regulation and changes in healthcare initiatives, developing and defending its intellectual property rights including those pertaining to the Company’s biotechnology assets, the development and approval of biotechnology/biopharmaceutical product candidates and Health IT products and such other additional risks and uncertainties discussed in the Company’s filings with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to the Company (or any person acting on the Company’s behalf) are qualified by the cautionary statements in this notice. MMRGlobal, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information.

Click here to see all recent news from this company

RALEIGH, NC–(Marketwire – November 30, 2010) – InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products development, integration and marketing Company announced today that it will exhibit at the 18^th Annual World Congress on Anti-aging Medicine and Biomedical Technologies, (A4M) convention held at the Mandalay Bay Convention Center in Las Vegas, Nevada on December 9-11.

“This convention provides an excellent opportunity for our Company to expose our products to the medical community as well as the industry press,” stated Gary Berthold, CEO of InoLife Technologies, Inc. “We at InoLife Technologies would like to invite those health-care professionals that are attending the convention to visit booth 240 to discuss opportunities and for demonstrations of the Company’s DNA-based testing products.” 

InoLife will take advantage of this forum to educate physicians and healthcare practitioners on the advantages and availability of the Company’s Plavix metabolizing test. This DNA-based testing procedure can identify how a patient’s genetic inheritance may affect the body’s response to the popular drug commonly used for patients with cardiovascular risks.

The A4M expects approximately 3000 professionals to attend the convention. It is billed to be the largest and most influential conference and expo worldwide on preventative medicine and bio-medical technologies. The A4M organization is comprised of 22,000-plus members that include physicians, health practitioners, scientists, government officials and members of the general public representing over 105 nations. Eighty-five percent (85%) of the organization’s members are physicians (MD, DO,MBBS) followed by 12% that consists of scientists, researchers, and health practitioners, leaving 3% that are government officials, members of the working press and the general public. 

The A4M is dedicated to educating physicians, scientists and health practitioners on biomedical sciences, breaking technologies and anti aging issues. A4M seeks to disseminate information concerning innovative science and research as well as treatment modalities designed to prolong the human lifespan.

About InoLife Technologies, Inc.
InoLife is poised to become one of the premier U.S. marketers of state-of-the-art DNA-based test products. Positioned for growth and success in a burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end users. The Company’s mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.

The principal customers of InoLife’s products and services are healthcare providers, physicians, practitioners, hospitals and outpatient facilities. InoLife will be marketing and distributing its products through traditional distribution channels. Additionally InoLife has developed certain products that can be sold directly to consumers and has created specific programs to reach those customers including e-commerce, direct sales, healthcare providers, pharmacies, distributors, retail sellers and specialty retailers.

TUSTIN, CA–(Marketwire – November 30, 2010) – Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the signing of a Letter of Intent (“LOI”) to form an exclusive distribution agreement and collaborative business development partnership with Colombia-based PROCAPS S.A. PROCAPS is a top tier Latin American healthcare distribution company currently commercializing oncology and other therapeutic products throughout countries in Latin America.

RPC and PROCAPS intend to structure a long-term exclusive distribution partnership to build market share and awareness for RPC’s U.S. FDA-cleared Onko-Sure® In Vitro Diagnostic (IVD) cancer test in Latin America. The Companies are working on the following terms:

• RPC and PROCAPS will evaluate strategies to commercialize RPC’s Onko-Sure® IVD cancer test as a medically and economically beneficial cancer test for patients in Colombia and other Latin American healthcare markets.
• PROCAPS will investigate the market opportunity for full-service distribution of RPC’s Onko-Sure® IVD cancer test kit to clinical reference labs, hospitals and cancer treatment centers in designated territories in Latin America.
• RPC will grant PROCAPS first rights for distribution of Onko-Sure® in Colombia, Venezuela, Peru, Ecuador, Bolivia, Panama, Guatemala, Dominican Republic, and El Salvador.

In selecting PROCAPS, RPC acknowledges the Company’s expertise in launching new healthcare products in key Latin American markets. PROCAPS has formed successful partnerships with large pharmaceutical companies including Wyeth, Merck, GSK, and Sanofi. Most recently, PROCAPS has become an exclusive distributor of a US-developed oncology therapeutic.

RPC Chairman and CEO Mr. Douglas MacLellan commented, “Cancer knows no borders, and Radient Pharmaceuticals is well positioned to combat this disease by supplying innovative diagnostic tests like Onko-Sure® on both a domestic and global level. Latin America has an escalating cancer challenge similar to other emerging economies and in working with PROCAPS S.A., RPC holds tremendous commercialization potential for the rapidly expanding Latin American healthcare market. We are eager to finalize our partnership with PROCAPS and begin the marketing and sales of Onko-Sure in this region.”

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – November 29, 2010) – ForceLogix Technologies Inc. (TSX-V: FLT) is pleased to announce that it filed its interim financial statements and Management’s Discussion and Analysis today for the quarter ended September 30, 2010. The financial statements are available for review on SEDAR, www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Click here to see all recent news from this company

WESTPORT, CT–(Marketwire – November 29, 2010) – African community groups are transforming the future for orphans and other children affected by HIV and AIDS thanks to U.S.-funded programs, Save the Children said.

“The United States is doing much more than providing lifesaving drug treatment when it comes to helping people around the world battle the AIDS crisis and it must continue to do so,” said Charles MacCormack, President and CEO of Save the Children. “One of the most remarkable changes is the creation of African community networks dedicated to supporting orphans and other children affected by HIV and AIDS.”

“It’s amazing how care and support can replace stigma and isolation when local groups are empowered to mobilize around children who have been orphaned and left vulnerable by HIV and AIDS,” MacCormack said.

More than 17 million children have lost one or both parents to AIDS. Many millions more children have reduced opportunities in life because HIV and AIDS have struck their families and communities. Most of these children are in Africa.

The United States President’s Emergency Plan for AIDS Relief (PEPFAR) has funded programs offering care and support to more than 3.6 million orphans and vulnerable children in Africa. Save the Children has led several of these large programs in Mozambique, Uganda, and Ethiopia and has put special emphasis on empowering local community groups to care for affected children. The result is sustainable change for children.

For World AIDS Day (Dec. 1), Save the Children has released a new multimedia video highlighting new hope for orphans and other children affected by AIDS in Ethiopia, where 530,000 children have benefited from U.S.-funded programs. 

“One of the most interesting changes involves Ethiopia neighborhood associations that originally formed to help poor families cover funeral expenses,” MacCormack said. “Today these groups have transformed to offer new hope to the living. They are helping children get an education, enough to eat, a place to live, and, perhaps most importantly, a renewed sense of community and loving support that they had lost to AIDS.”

See the video and learn how you can help support children affected by HIV and AIDS here:
www.savethechildren.org/worldAIDSday2010

Save the Children is the leading, independent organization that creates lasting change for children in need in the United States and 120 countries around the world.

NEW YORK, NY–(Marketwire – November 29, 2010) – MedLink (OTCBB: MLKNA), a leading provider of health information technology solutions, today announced that it has closed an aggregate of $2.25 million in financing. Aegis Capital Corp, sole placement agent and exclusive investment banker to MedLink, placed $1.0 million through a private placement, and an additional $1.25 million in capital through the sale of convertible notes sold exclusively to institutional investors. The investment capital proceeds will be used to fund increased sales and marketing, working capital needs of the Company, and the acquisition of MedAppz which was announced earlier this month.

“We are extremely pleased to have the support of our investors who affirm our corporate vision, and the overwhelming interest in the offering is a testament to the MedLink team and the cutting edge technology we are providing to the healthcare market,” said Ray Vuono, CEO of MedLink International, Inc. “With this financing, the company is well positioned to deliver its suite of Electronic Health Record (EHR) and Healthcare Information Technology communication platforms, to meet the increasing demand of the industry as healthcare facilities of all sizes are adopting EHR technology to take advantage of the efficiencies and the incentives both on a State and Federal level.”

David Bocchi, Director of Investment Banking at Aegis Capital, said, “MedLink represents a rare and exciting opportunity in a competitive and consolidating space where it continues to demonstrate it has the tools and resources necessary to successfully become an industry leader.” He added, “The management team was instrumental in swiftly securing the capital in a placement with overwhelming investor demand, and we look forward to providing the company with the continued support necessary to assist in its growth.”

About MedLink

MedLink is a healthcare IT company providing the medical community with products and services for the creation, management, and sharing of medical information. The company’s flagship product, MedLink TotalOffice EHR 3.1, a CCHIT Certified® 08 Ambulatory EHR, provides physicians with full EHR and practice management functionality. For more information regarding MedLink’s products and services, please visit www.medlinkus.com.

About Aegis

Aegis Capital is a full-service boutique brokerage operation focused on middle-market corporate finance, research, and valuation services. Aegis actively manages over $2 billion of retail customer assets with over 200 registered representatives in 8 corporate locations. Aegis Capital Corporation was founded in 1984 by Robert Eide, the current CEO and Chairman. Its origins were based on servicing the specific needs of an extremely affluent customer base. For more information, please visit the Aegis website at www.aegiscapcorp.com.

Safe Harbor Statement

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, outlined in our 2009 Annual Report on Form 10-Kavailable through www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

LOS ANGELES, CA–(Marketwire – November 29, 2010) – Fresh Start Private (OTCQX: CEYY) (PINKSHEETS: CEYY), a leader in the alcohol treatment and rehabilitation industry, today announced that its first facility is operational and able to treat up to 15 patients a day with a potential revenue of $120 Million per year per clinic.

According to the National Institute of Health there are an estimated 17.6 million alcoholics in the USA.

Fresh Start Private’s fully licensed and certified medical facility has three treatment rooms that are each able to process up to five patients per day. As part of the treatment, trained medical doctors insert Fresh Start Private’s exclusively licensed specially formulated biodegradable Naltrexone implant just beneath the skin below the patient’s lower abdominal area.

The FDA approved Naltrexone blocks the part of the brain that “feels” pleasure when patients use alcohol. When these areas of the brain are blocked, patients feel less need to drink alcohol, and they can stop drinking more easily. Once medical intervention has reduced the physical need for alcohol, the program goes on to address the patient’s physiological needs. The combination of these treatments results in sobriety in nearly 100% of all patients.

Fresh Start Private is the only alcohol treatment program to offer a single-administration, long-acting, Naltrexone implant procedure.

 “At Fresh Start Private we have created a comprehensive recovery program that includes state-of-the-art medical intervention, individually tailored Fresh Start Private Coaching Program sessions, rebuilding of family and friend connections and post-treatment continuing care,” stated Dr. Jorge Andrade, CEO of the Company. “Only through a comprehensive treatment solution can a patient have his/her best chance at recovery.”

There are many benefits to the Fresh Start Program compared to other traditional alcohol treatments. As the Fresh Start treatment is administered on an outpatient basis, there is no need for patients to leave their work and family for any extended period of time. In fact, many in treatment return to work the next day and not even co-workers or family members know they are being treated. The Fresh Start team has the experience to handle all alcohol addiction scenarios. The Fresh Start Private program can be less expensive than many traditional treatment centers.

About Fresh Start Private

Fresh Start Private is an alcohol addiction, alcohol withdrawal, alcohol abuse treatment and alcohol detox rehabilitation company on the leading edge of the alcohol addiction treatment. The Company has an exclusive license on a highly effective treatment (Naltrexone Implant) that delivers therapeutic levels of Naltrexone that significantly reduces patients’ cravings for alcohol.

Please visit http://www.freshstartprivate.com.

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “potential,” “up to,” “estimate,” “over,” “intend,” “can be,” “nearly” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Fresh Start filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to the ability of Fresh Start to manage product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on Fresh Start’s website does not constitute a part of this release.

MUNDELEIN, IL–(Marketwire – November 29, 2010) – Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of healthcare supplies, announced today the signing of a cost-management prime vendor agreement with Cleveland, Ohio-based St. Vincent Charity Medical Center. The five year agreement is anticipated to save the hospital an estimated $2.5 million over the term of the contract.

St. Vincent’s patient-centered focus on quality has earned them the HealthGrades Distinguished Hospital Award for Clinical Excellence for five consecutive years (2006-2010). In keeping with their focus, the hospital plans to take advantage of the many clinical programs Medline offers including the Pressure Ulcer Prevention Program, the Perioperative Pressure Ulcer Prevention Program and the ERASE CAUTI (catheter-associated urinary tract infection) Program. Each of these evidenced-based programs was designed to help improve quality and safety outcomes, increase patient satisfaction and reduce errors for healthcare facilities.

Under the terms of the contract, Medline is expected to generate more than $10 million in annual medical and surgical product sales from the partnership over the term of the agreement. Under the agreement, Medline will provide its broad array of Medline brand medical and surgical products, including surgical procedure trays, patient care products, disposable protective gowns, exam gloves and bandages.

Cost savings and customer service were two key factors in making Medline St. Vincent Charity Medical Center’s prime vendor. Medline will drive cost savings to St. Vincent through delivering Medline manufactured products direct to the healthcare facility from Medline’s newly built 300,000 square foot, state-of-the-art distribution facility in Canton, OH. Medline will also deliver cost savings by reducing distribution fees on other national brand products and product standardization. In addition, Medline will provide enhanced reporting capabilities and offer comprehensive product utilization, education and practical solutions to help the facility control costs and improve patient care. 

About Saint Vincent Charity Hospital
St. Vincent Charity Medical Center is Cleveland’s faith-based, high-quality healthcare provider, with distinguished doctors and caregivers devoted to treating every patient with clinical excellence and compassionate care. St. Vincent Charity Medical Center is home to the renowned Spine and Orthopedic Institute and the Center for Bariatric Surgery. Owned by the Sisters of Charity Health System, St. Vincent Charity Medical Center delivers health for the heart of Cleveland. The Sisters of Charity Health System is a family of hospitals, grant-making foundations, elder care and outreach organizations devoted to healing individual, families and communities. For more information, visit www.stvincentcharity.com.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

MONTVALE, NJ–(Marketwire – November 29, 2010) – SRS, the leading provider of productivity-enhancing technology and services for high-performance specialty practices today announced that Indiana Hand to Shoulder Center has selected the SRS Unified Desktop™ for its 35 providers. Indiana Hand to Shoulder Center has 6 office locations providing specialized upper extremity treatment to the greater Indianapolis area.

“The value of an integrated package far exceeds the sum of the benefits of the individual parts,” says James J. Creighton, Jr., M.D., Indiana Hand to Shoulder Center. “Accessing PACS images directly from the patient’s chart in the EMR — without having to open another application and toggle back and forth — will be a huge time-saver for me.”

“The efficiency and ease of use produced by incorporating three vital core technologies into one product is invaluable,” says Audra Frezza, Chief Information Officer, Indiana Hand to Shoulder Center. “One of the reasons we chose SRS is its reputation for the highest levels of customer satisfaction, as well as its drive to stay at the cutting edge of technology. The success level achieved by SRS in the Orthopaedic arena is unparalleled.”

“The Unified Desktop is unique in the EMR industry,” according to Evan Steele, CEO of SRSsoft. “The open architecture upon which our EMR software is built allows us to deliver all clinical and business applications through one seamless user interface. The Unified Desktop is just one of the many ways that SRS boosts productivity for high-performance practices like Indiana Hand to Shoulder Center.”

About SRS
SRS is the leading provider of productivity-enhancing EMR technology and services for high-performance specialty practices — with a successful adoption rate unparalleled in the industry. Offered via the Unified Desktop™, the robust EMR, SRS CareTracker PM, and SRS PACS increase speed, free physicians’ time, boost revenue, and heighten patient care and satisfaction. For more information on SRS, visit www.srssoft.com, e-mail [email protected], fax 201.802.1301, or call 800.288.8369.

About Indiana Hand to Shoulder Center
Indiana Hand to Shoulder Center began in 1971 as a private hand surgery practice. Since then, it has grown to become a renowned center of excellence, recognized across the world for their specialization in problems and injuries of the hand, wrist, elbow and shoulder. Now located on the northwest side of Indianapolis, Indiana Hand to Shoulder Center is the largest free-standing facility of its kind in the world. For more information, visit www.indianahandtoshoulder.com.

OMAHA, NE–(Marketwire – November 29, 2010) – RadTrac, an informatics and biotech solutions firm, has created breakthrough radiation dosage tracking technology that will track and prevent unnecessary radiation exposure for patients and limit liability for hospitals. 

Overexposure to radiation can lead to serious health problems including cancer. There are currently standards set by the American Medical Association for radiation limits but no way exists to track how much cumulative radiation a patient receives. 

Patient radiation levels are tracked and monitored through RadTrac’s proprietary Radiation Dosage Tracking System (RDTS) software engine. Before a patient’s exposure level reaches an unsafe amount, health care providers are alerted and can review diagnostic options before exposing that patient to more radiation, making facilities aware of the potential for overexposure. RDTS allows the physician and medical team to concentrate on practicing medicine and make informed decisions about radiation exposure in real-time.

“The RDTS will not only prevent overexposure and track cumulative exposure, but can also be used as a research tool in the future,” said Gena Kriewald, Co-founder and Vice President of Clinical Development. “The educational benefits that come from creating a national database of radiation exposure on a variety of modalities are immeasurable. By sharing dosage level information across a network of hospitals throughout the nation, facilities can learn not only how to limit exposure but also what modalities are most effective while offering the least amount of radiation.”

“We are currently tracking several facilities with various modalities in regions throughout the United States,” said RadTrac Chief Executive Officer Jesse Fisher. “The RadTrac system takes a proactive approach to preventing radiation exposure by tracking the amount of radiation patients are exposed to — both at the procedure level and cumulatively — and alerting medical professionals before high levels of radiation exposure are reached.”

RadTrac implemented the initial phase of RDTS testing in March of 2010, and completed beta testing in June. The product is now available for release.

About RadTrac: RadTrac is a joint venture of Binovia, Inc., an informatics and biomedical services firm, and Study Overflow Solutions, Inc., (SOS), a teleradiology and practice management firm. RadTrac, a radiology software solutions firm, provides systems and implementation to medical facilities including hospitals, radiology departments and clinics to prevent radiation overexposure and promote x-ray and radiation safety. 

WOBURN, MA–(Marketwire – November 29, 2010) – Yankee Alliance (www.yankeealliance.com), a Group Purchasing Organization for Healthcare industry member organizations, has approved Service Point USA (www.servicepointusa.com) as a vendor for the provision of Large Format Graphics and Signage.

There are 69 YA member organizations which consist of Hospitals and Medical Centers. These are located primarily in the Northeast region of the U.S. where Service Point USA’s service center locations are concentrated.

In addition, YA has thousands of Affiliate Members throughout the U.S. that include Long Term Care Facilities, Clinics, Rehabilitation Facilities, and other Healthcare related businesses. These are potential users of Service Point’s products and services as well.

Member buyers include multiple professionals from each organization in departments of Marketing and Communications, Public Relations, Purchasing, Training and Education, and Facilities Management groups.

Service Point is unique among YA vendors with its specialization in Large Format Graphics, Signage, and Way Finding Systems. Example applications of these products and services for the Healthcare industry include:

• Facility Way / Finding signage systems, interior and exterior
• Educational / Public Relations Displays
• Environmental Graphics / Murals / Posters
• Eco-Friendly Display Graphics
• Information Graphics / HIPAA Communication Posters
• Clean Room / Laboratory moisture-resistant posters and safety signs
• Floor Graphics and Way Finding visual aids
• Event Banners and Flags
• ADA Compliant Signage
• Vehicle Graphics, Vinyl Lettering

YA buyers may send orders and graphic files for production electronically via their unique, online Digital Storefront site established by Service Point for the use of YA members only. Service Point’s Digital Storefront product provides authorized users a secure and efficient means to transmit and store files for future access within a custom branded environment.

The Yankee Alliance agreement augments Service Point USA’s continued pursuit of business within the Healthcare industry, one of its focus markets.

About Service Point
Service Point provides tools and services for greater efficiency in document, print, and information management via networked service centers, online, and through On-Site Services programs with client firms nationwide.

Service Point USA is a subsidiary of Service Point Solutions. It employs 2,400 people across 8 countries through a network of 127 service centers and 794 facilities management programs. SPS is headquartered in Spain and listed on the Madrid and Barcelona stock exchanges (ticker: SPS.MC).

SEATTLE, WA–(Marketwire – November 29, 2010) – With changing consumer expectations and the increased use of mobile devices, healthcare organizations need to find ways to engage members and patients in new ways. But, if achieving behavioral change was as simple as sending a text message, everyone would be eating a healthy diet, exercising regularly and would never smoke.

In this complimentary Webinar, Dr. George Gellert, senior healthcare advisor for Varolii Corporation, and Elizabeth Boehm, principal analyst at Forrester Research, will share insights into how healthcare consumers’ expectations are changing and how healthcare organizations can use mobile devices to engage members and patients in an effective way.

WHEN: Thursday, December 2, 2:00 – 2:45 p.m. ET / 11:00 – 11:45 a.m. PT

WHAT: A complimentary Webinar discussing why patient communications are critical to changing patient behaviors. Attendees will learn:

• How patient preferences impact the effectiveness of communications
• How to improve program adherence with a cross-channel communication strategy
• Why patient communications will be critical to achieving healthier outcomes

WHO: Dr. George Gellert, MD, senior healthcare advisor for Varolii, is a physician epidemiologist and executive with 20 years of experience in health information and communication. Dr. Gellert is the former Chief Medical Officer and EVP for HCORP Inc. and Senior VP of Strategic Alliances at WebMD. 

Elizabeth Boehm, principal analyst at Forrester Research, joined Forrester in 1997 and became co-founder of Forrester’s healthcare and life sciences practice in 1999. She continues to lead the healthcare and life sciences research community, and her own research focuses heavily on the topic areas relevant to healthcare customer experience.

REGISTER: https://www.varolii.com/en/go/2010/smshcwebinar